This symposium will offer an update on peripheral neuropathic pain, including recent insights into the role of peripheral-specific voltage-gated sodium channels (VGSC), as well as evidence from randomized-controlled trials of first line pharmacologic agents, published subsequent to the 2007 neuropathic pain guidelines. The role of VGSCs beyond the well-established Na(v)1.7, Na(v)1.8 and Na(v)1.9 is being investigated, such as Na(v)1.1, Na(v)1.2 and Na(v)1.8 in patients with CRPS Type 1 and PHN. Meanwhile, the body of evidence on efficacy and safety of agents evaluated in the guidelines has grown substantially since 2007. A systematic review and update of this evidence will be provided.
The Roles of Sodium Channels in Nociception: Implications for Mechanisms of Neuropathic Pain
New Developments in the Treatment Algorithm for Peripheral Neuropathic Pain
Faculty
Oscar de Leon-Casasola, MD
John N. Wood, FMedSci FRS
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Miller Medical Communications, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
This activity is supported by an educational grant from Endo Pharmaceuticals Inc.
|